Prurigo nodularis is a chronic skin condition that impacts an estimated 75,000 individuals in the United States (US). This condition is characterized by persistent and intense itching, significantly impacting the quality of life for those affected. Research has shown a higher prevalence of prurigo nodularis among individuals with certain comorbidities, such as mental health, endocrine, […]
Read MoreWelcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication aflibercept, marketed under the brand name Eylea by Regeneron Pharmaceuticals, Inc. Eylea a is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema […]
Read More
A list of all the FDA approved medications in September 2024.
Read More
The Food and Drug Administration (FDA) protects public health by guaranteeing the safety, effectiveness, and security of pharmaceuticals and medical devices. The Prescription Drug User Fee Act (PDUFA) date marks the deadline by which the FDA must complete its review of drug applications. Occasionally, an advisory committee (AdCom) meeting is convened to assess the drug […]
Read MoreWelcome to the latest installment of our Guidelines+ Monographs Series. In this edition, we will delve into the medication vedolizumab, marketed under the brand name Entyvio by Takeda Pharmaceuticals. Entyvio is an integrin receptor antagonist indicated in adults for the treatment of moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn’s […]
Read MoreWelcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication aripiprazole, marketed under the brand name Abilify Asimtufii by Otsuka Pharmaceutical Co., Ltd. Abilify Asimtufii (aripiprazole) is a long-acting injectable atypical antipsychotic for the treatment of schizophrenia and bipolar I disorder. It was initially approved in […]
Read More
Alopecia areata is a prevalent autoimmune skin disease characterized by the development of patches of non-scarring hair loss. According to the National Alopecia Areata Foundation, nearly 7 million people in the United States (US) and 160 million worldwide are affected by alopecia areata or will be affected by it at some point. Currently, it is […]
Read More
Pompe disease, also known as acid maltase disease and glycogen storage disease II, is a rare genetic disorder that results in progressive weakness in the heart and skeletal muscles. This debilitating condition is caused by mutations in a gene responsible for producing an enzyme called acid alpha-glucosidase (GAA). This enzyme plays a crucial role in […]
Read MoreWelcome to the newest installment of our Guidelines+ Monographs Series. Today, we will be exploring the medication naltrexone, specifically the injectable form marketed under the brand name Vivitrol by Alkermes, Inc. Vivitrol is an opioid antagonist that was first approved in 2006. It is prescribed for the treatment of alcohol dependence and to block the […]
Read MoreWelcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication brexpiprazole, marketed under the brand name Rexulti by Otsuka America Pharmaceutical, Inc and Lundbeck LLC. Rexulti, an atypical antipsychotic, received initial approval in 2015. It is indicated for use as an adjunctive therapy to antidepressants for […]
Read More